Anifrolumab-Fnia

Introduction Overview

Generic Name

anifrolumab-fnia

Brand Name

Saphnelo

Dosage Form

injection, for intravenous use

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Anifrolumab-fnia (Saphnelo) is administered intravenously, and as such, it bypasses the gastrointestinal tract and enters directly into the systemic circulation. The intravenous route ensures 100% bioavailability. Following infusion into the bloodstream, the drug rapidly distributes within the vascular compartment and target tissues expressing type I interferon receptors. The absorption phase typical of oral drugs is therefore not applicable, but the rate of administration (over approximately 30 minutes) is critical to maintain safety and reduce infusion reactions.

Distribution:
After administration, anifrolumab-fnia displays distribution characteristics typical of monoclonal antibodies. It primarily remains within the vascular and interstitial spaces due to its large molecular size and hydrophilicity. The volume of distribution is relatively low compared to small-molecule drugs, reflecting confinement largely to extracellular fluid. Anifrolumab specifically binds to type I interferon receptors, which are abundantly expressed on immune cells such as plasmacytoid dendritic cells, B-cells, and T-cells, facilitating drug-target engagement. The drug does not cross the blood-brain barrier significantly, limiting central nervous system exposure.

Metabolism:
Being a monoclonal antibody, anifrolumab is metabolized via proteolytic catabolism into small peptides and amino acids through reticuloendothelial system pathways, predominantly in the liver, spleen, and other tissues containing immune cells. This process does not involve cytochrome P450 enzymes, thereby reducing concerns for classic drug-drug interactions seen with small molecules metabolized hepatically. The metabolic clearance is consistent with other human monoclonal antibodies.

Elimination:
Elimination of anifrolumab-fnia follows typical monoclonal antibody kinetics, involving cellular uptake and lysosomal degradation. The terminal half-life ranges approximately from 18 to 21 days, supporting the regimen of monthly (every 4 weeks) intravenous dosing. The drug does not undergo renal excretion unchanged, and its elimination is not impacted significantly by renal or hepatic impairment. Elimination pathways and half-life ensure sustained receptor blockade across the dosing interval, contributing to its efficacy in systemic lupus erythematosus (SLE).

Dosage Forms

Available Dosage Forms:
Saphnelo is supplied as a sterile, preservative-free, single-dose vial containing 300 mg of anifrolumab-fnia in 2 mL solution (150 mg/mL). The formulation is a clear to slightly opalescent, colorless to pale brown solution intended for intravenous infusion.

Dosages for Adults and Adolescents:
The recommended dosage for adults with moderate to severe systemic lupus erythematosus (SLE) is 300 mg administered by intravenous infusion over approximately 30 minutes every 4 weeks. Dosing adjustments have not been established for special populations such as pediatric patients; currently, Saphnelo is not approved for use in patients younger than 18 years.

Specific Patient Populations:
Saphnelo has not been studied extensively in patients with severe active lupus nephritis or severe active central nervous system lupus, and thus is not recommended for these conditions. There is no dose adjustment recommended based on renal or hepatic impairment due to its monoclonal antibody elimination pathways. Use in pregnant or breastfeeding women should be approached with caution; vaccination status should be updated prior to initiation, and live vaccines should be avoided during treatment. Clinical guidelines emphasize maintaining a minimum interval of 14 days between infusions in cases of delayed dosing or missed appointments.

Clinical guidelines advise that infusions be administered under medical supervision in settings prepared for managing infusion reactions and potential hypersensitivity.

Mechanism Of Action

Anifrolumab-fnia, the active ingredient in Saphnelo, is a fully human monoclonal antibody designed to target and bind to the type I interferon (IFN) receptor subunit 1 (IFNAR1). This receptor is a critical component of the type I interferon signaling pathway, which is overactivated in patients with systemic lupus erythematosus (SLE).

Upon binding to IFNAR1, anifrolumab inhibits the receptor’s ability to engage type I interferons, including IFN-α, IFN-β, and IFN-ω. This blockade prevents receptor dimerization and subsequent activation of intracellular signaling cascades. Primarily, it inhibits the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which ordinarily leads to transcription of interferon-stimulated genes (ISGs) involved in inflammatory and immune responses.

By suppressing this pathway, anifrolumab reduces the transcription of pro-inflammatory cytokines, chemokines, and costimulatory molecules. This mechanism attenuates the pathological immune activation and autoantibody production characteristic of SLE, thereby reducing systemic inflammation, tissue damage, and clinical disease activity.

Clinically, blocking type I interferon signaling addresses a key pathogenic driver in SLE, providing targeted immunomodulation distinct from broad immunosuppressants. Compared to other biologics like belimumab, which targets B-lymphocyte stimulator (BLyS), anifrolumab offers a complementary approach by directly interfering with cytokine signaling upstream of diverse immune cell activation. Clinical trials have demonstrated that anifrolumab's mechanism results in significant reduction in SLE disease activity with a favorable safety profile over 52-week treatment periods.

Pharmacological Actions

Selective inhibition of type I interferon receptor signaling.
Reduction of interferon-stimulated gene expression.
Modulation of innate and adaptive immune responses.
Suppression of pro-inflammatory cytokine and chemokine production.
Decrease in autoantibody formation through immune regulation.
Attenuation of systemic inflammation in systemic lupus erythematosus (SLE).
Immunosuppressive activity without general cytotoxic effects.
Decreased activation of plasmacytoid dendritic cells and downstream immune cells.
Reduction of lupus flare frequency and severity through targeted immune modulation.
Minimal interaction with cytochrome P450 enzymes, reducing metabolic drug interactions.
Intravenous monoclonal antibody with prolonged half-life enabling monthly dosing.
Lack of direct nephrotoxic or neurotoxic effects as demonstrated in clinical trials.
Inhibition of JAK-STAT signaling pathway via receptor blockade.

Therapeutic Or Clinical Uses

Treatment of moderate to severe systemic lupus erythematosus (SLE) in adults.
Adjunct therapy in adults receiving standard lupus medications to reduce disease activity.
Prevention or reduction of lupus flares in systemic lupus erythematosus.
Improvement of symptoms including fatigue, joint pain, and skin lesions associated with SLE.
Reduction of the need for higher doses of corticosteroids or other immunosuppressants.
Targeted therapy for patients with elevated type I interferon gene signatures.
Management of SLE patients inadequately responsive to standard care.
Not indicated for severe active lupus nephritis or severe active central nervous system lupus.
Part of the treatment arsenal for autoimmunity characterized by interferon overactivity.
Potential to improve quality of life by controlling systemic inflammation.
Used in combination with other immunomodulatory agents under specialist supervision.
Selected for patients aged 18 years and older with diagnosed SLE.
Provides an alternative to conventional immunosuppressants with different side effect profile.
Facilitates long-term disease control through sustained receptor blockade.
Authorized for use following FDA approval in 2021 for SLE management.

Side Or Adverse Effects

Upper respiratory tract infections, including nasopharyngitis.
Infusion-related reactions such as flushing, rash, or fever during or shortly after administration.
Cough and bronchitis reported in clinical trials.
Increased risk of herpes zoster (shingles) infections.
Serious infections due to immunosuppression, including bacterial, viral, and fungal infections.
Hypersensitivity reactions, including rare anaphylaxis.
Potential increased risk of malignancies due to immune modulation.
Gastrointestinal symptoms including diarrhea and stomach discomfort reported infrequently.
Fatigue and headache reported as mild to moderate adverse effects.
Injection site reactions are uncommon due to intravenous route but possible.
Laboratory abnormalities such as transient lymphopenia.
Risk of reduced vaccine efficacy, especially live-attenuated vaccines during treatment.
Potential exacerbation of pre-existing infections necessitating close monitoring.
Rare reports of infusion site pain or phlebitis.
General adverse effects consistent with monoclonal antibody therapies, including hypersensitivity and immunogenicity.

Precautions

Do not initiate therapy in patients with active, severe infections until resolved.
Ensure vaccination status is updated prior to initiation; avoid live vaccines during treatment.
Monitor for signs and symptoms of infection throughout therapy.
Use caution in patients with previous or current malignancies; discuss risk-benefit.
Assess for hypersensitivity to anifrolumab-fnia or any inactive ingredients before administration.
Avoid use in pregnant women unless potential benefits justify potential risks.
Use with caution in immunocompromised patients or those receiving other immunosuppressive agents.
Regular clinical and laboratory monitoring recommended to detect early adverse events.
Educate patients to report symptoms such as fever, chills, or rash promptly.
Avoid abrupt discontinuation; follow healthcare provider instructions for dosing schedule.
Maintain a minimum interval of 14 days between infusions if dose delayed or missed.
Use caution when coadministered with other biologics or monoclonal antibodies.
Consider immunological impact in patients with autoimmune comorbidities.
Ensure storage conditions between 2°C and 8°C (36°F to 46°F) to maintain drug stability.
Do not shake the vial or freeze the product to prevent denaturation.

Warnings

Risk of serious and potentially fatal infections due to immunosuppression.
Serious hypersensitivity and anaphylactic reactions may occur during or after infusion.
Avoid live vaccines during treatment as immunosuppression may reduce vaccine efficacy and increase risk of infection.
Potential increased risk of malignancies observed with immunosuppressive therapies.
Not evaluated for safety and efficacy in severe active lupus nephritis or severe CNS lupus; use is not recommended.
Pregnancy safety has not been established; potential effects on fetal immune system unknown.
Use caution in patients with a history of recurrent infections.
Potential for infusion reactions warrants administration by healthcare professionals prepared to manage such events.
Delayed dosing or interruption may reduce therapeutic effectiveness; maintain dosing intervals as recommended.
Patients should be closely monitored for signs of infection and malignancy during and after treatment.
Immunomodulation may mask signs and symptoms of infection, delaying diagnosis.
Risk-benefit assessment required before initiating in patients with history of malignancy.
Avoid concomitant use with other immunosuppressive biologics without careful consideration.
Reporting of adverse events to FDA or healthcare provider is encouraged to monitor safety profile.
Immediate medical attention required for any signs of allergic reactions.

Contraindication

Known hypersensitivity to anifrolumab-fnia or any component of the formulation.
Active, severe infections that are untreated or uncontrolled at the time of planned initiation.
Use in pediatric patients under age 18 due to lack of established safety and efficacy.
Severe active lupus nephritis due to lack of efficacy data.
Severe active central nervous system lupus not recommended due to absence of clinical evaluation.
Concomitant administration of live vaccines during treatment or until 6 months post-therapy.
Patients with previous anaphylactic reactions to monoclonal antibodies should avoid use or be closely monitored.
Conditions where immunosuppression poses unacceptable risk or complications.
Use with caution or avoid in patients with history of malignancies until adequate risk assessment.
Contraindicated if there is known or suspected infection with tuberculosis or other opportunistic infections.

Drug Interactions

Concurrent use with live attenuated vaccines is contraindicated due to immune suppression reducing vaccine efficacy and risk of infection.
No significant metabolism via cytochrome P450 enzymes reduces potential for pharmacokinetic drug-drug interactions.
Potential additive immunosuppressive effects when used with other biologics or immunosuppressants such as corticosteroids, methotrexate, or azathioprine.
Interactions with other monoclonal antibodies may increase risk of infections or infusion reactions.
No known significant interactions with common medications used in lupus patient populations such as NSAIDs or antimalarials.
Caution advised when co-administered with other agents impairing immune function.
No expected interaction with drugs altering hepatic or renal clearance due to monoclonal antibody elimination via proteolytic pathways.
No evidence of interaction with herbal supplements, but patients should inform providers of all herbal or vitamin use.
No documented alterations in pharmacodynamics or pharmacokinetics with concomitant medications in clinical trials.
Future interactions could be identified; ongoing monitoring recommended.
Potential for immunogenicity-related neutralization when combined with other biologics targeting immune pathways.
Live vaccines should be administered prior to starting therapy to avoid diminished immunogenic response.
Patients should report all concomitant drug use to healthcare providers for comprehensive management.
No established interaction with anticoagulants or antiplatelet agents but patients require monitoring for infection risk.
Monitoring recommended when combined with drugs that may mask infection symptoms (e.g., corticosteroids).

Preparations Of The Drug

Saphnelo is supplied as a sterile single-dose vial containing 300 mg anifrolumab-fnia in 2 mL solution at a concentration of 150 mg/mL.
Formulated as a clear to slightly opalescent, colorless to pale brown aqueous solution.
Inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, L-lysine hydrochloride, trehalose dihydrate, polysorbate 80, and water for injection.
Packaged in glass vials designed for single-use intravenous infusion preparation.
Must be stored refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light.
Do not freeze the product as this can compromise monoclonal antibody integrity.
Do not shake the vial to avoid mechanical denaturation or aggregation of the antibody.
Prepared by dilution into compatible infusion solutions by healthcare providers prior to administration.
Supplied by AstraZeneca AB, Sweden, and distributed by AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Manufactured under sterile conditions adhering to biological product standards.
No preservatives are included, necessitating aseptic technique during preparation.
Available only through specialized centers due to the need for intravenous infusion administration.
Handling requires trained medical staff familiar with monoclonal antibody therapies.
Packaging includes clear labeling with storage, dosage, and administration instructions.
Disposal should follow biohazard protocols for injectable biologic preparations.